160 related articles for article (PubMed ID: 31933586)
1. Emulsion of Olive Oil and Calcium Hydroxide for the Prevention of Radiation Dermatitis in Hypofractionation Post-Mastectomy Radiotherapy: A Randomized Controlled Trial.
Chitapanarux I; Tovanabutra N; Chiewchanvit S; Sripan P; Chumachote A; Nobnop W; Tippanya D; Khamchompoo D
Breast Care (Basel); 2019 Dec; 14(6):394-400. PubMed ID: 31933586
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation.
Ho AY; Olm-Shipman M; Zhang Z; Siu CT; Wilgucki M; Phung A; Arnold BB; Porinchak M; Lacouture M; McCormick B; Powell SN; Gelblum DY
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):325-333. PubMed ID: 29726361
[TBL] [Abstract][Full Text] [Related]
3. Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity.
Chitapanarux I; Klunklin P; Pinitpatcharalert A; Sripan P; Tharavichitkul E; Nobnop W; Onchan W; Chakrabandhu S; Jia-Mahasap B; Euathrongchit J; Wannasopha Y; Srisuwan T
Radiat Oncol; 2019 Oct; 14(1):175. PubMed ID: 31610801
[TBL] [Abstract][Full Text] [Related]
4. Acute radiation-induced skin toxicity in hypofractionated vs. conventional whole-breast irradiation: An objective, randomized multicenter assessment using spectrophotometry.
Schmeel LC; Koch D; Schmeel FC; Röhner F; Schoroth F; Bücheler BM; Mahlmann B; Leitzen C; Schüller H; Tschirner S; Fuhrmann A; Heimann M; Brüser D; Abramian AV; Müdder T; Garbe S; Vornholt S; Schild HH; Baumert BG; Wilhelm-Buchstab TM
Radiother Oncol; 2020 May; 146():172-179. PubMed ID: 32171945
[TBL] [Abstract][Full Text] [Related]
5. A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients.
Ingargiola R; De Santis MC; Iacovelli NA; Facchinetti N; Cavallo A; Ivaldi E; Dispinzieri M; Franceschini M; Giandini C; Romanello DA; Di Biaso S; Sabetti M; Locati L; Alfieri S; Bossi P; Guglielmo M; Macchi F; Lozza L; Valdagni R; Fallai C; Pignoli E; Orlandi E
Radiat Oncol; 2020 Aug; 15(1):193. PubMed ID: 32791985
[TBL] [Abstract][Full Text] [Related]
6. Topical use of olive oil preparation to prevent radiodermatitis: results of a prospective study in nasopharyngeal carcinoma patients.
Cui Z; Xin M; Yin H; Zhang J; Han F
Int J Clin Exp Med; 2015; 8(7):11000-6. PubMed ID: 26379896
[TBL] [Abstract][Full Text] [Related]
7. Double-Blind, Placebo-Controlled Pilot Study of Processed Ultra Emu Oil Versus Placebo in the Prevention of Radiation Dermatitis.
Rollmann DC; Novotny PJ; Petersen IA; Garces YI; Bauer HJ; Yan ES; Wahner-Roedler D; Vincent A; Sloan JA; Issa Laack NN
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):650-8. PubMed ID: 25936812
[TBL] [Abstract][Full Text] [Related]
8. 5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.
Poppe MM; Yehia ZA; Baker C; Goyal S; Toppmeyer D; Kirstein L; Chen C; Moore DF; Haffty BG; Khan AJ
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):694-700. PubMed ID: 32289474
[TBL] [Abstract][Full Text] [Related]
9. Trends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis.
Venigalla S; Guttmann DM; Jain V; Sharma S; Freedman GM; Shabason JE
Clin Breast Cancer; 2018 Oct; 18(5):e899-e908. PubMed ID: 29550285
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation.
Orecchia R; Rojas DP; Cattani F; Ricotti R; Santoro L; Morra A; Cambria R; Luraschi R; Dicuonzo S; Ronchi S; Surgo A; Dell' Acqua V; Veronesi P; De Lorenzi F; Fodor C; Leonardi MC; Jereczek-Fossa BA
Med Oncol; 2018 Feb; 35(3):39. PubMed ID: 29442173
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial.
Khan AJ; Poppe MM; Goyal S; Kokeny KE; Kearney T; Kirstein L; Toppmeyer D; Moore DF; Chen C; Gaffney DK; Haffty BG
J Clin Oncol; 2017 Jun; 35(18):2037-2043. PubMed ID: 28459606
[TBL] [Abstract][Full Text] [Related]
12. Feasibility, Tolerance, and Quality of Life for Hypofractionation Versus Conventional Fractionation for Post-mastectomy Radiotherapy in Indian Patients.
Malik D; Singh A; Birajdar MM; Vyas VJ
Cureus; 2022 Mar; 14(3):e23497. PubMed ID: 35494973
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
14. Assessment of acute toxicities and early local recurrences in post mastectomy breast cancer patients by accelerated hypofractionated radiotherapy; a single arm clinical trial.
Vijayaraghavan N; Vedasoundaram P; M Mathew J; Menon A; Kannan B
J BUON; 2020; 25(5):2265-2270. PubMed ID: 33277844
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions.
Wang S; Wen G; Tang Y; Yang Y; Jing H; Wang J; Zhang J; Zhao X; Sun G; Jin J; Song Y; Liu Y; Fang H; Zhang Y; Li Y
BMC Cancer; 2020 Aug; 20(1):792. PubMed ID: 32838753
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial.
Chatterjee S; Chakraborty S;
Trials; 2020 Sep; 21(1):819. PubMed ID: 32998747
[TBL] [Abstract][Full Text] [Related]
17. Immediate tissue expander or implant-based breast reconstruction does not compromise the oncologic delivery of post-mastectomy radiotherapy (PMRT).
Jethwa KR; Kahila MM; Whitaker TJ; Harmsen WS; Corbin KS; Park SS; Yan ES; Lemaine V; Boughey JC; Mutter RW
Breast Cancer Res Treat; 2017 Jul; 164(1):237-244. PubMed ID: 28417333
[TBL] [Abstract][Full Text] [Related]
18. Post-mastectomy radiotherapy is associated with improved overall survival in T3N0 patients who do not receive chemotherapy.
Almahariq MF; Quinn TJ; Siddiqui ZA; Thompson AB; Jawad MS; Chen PY; Gustafson GS; Dilworth JT
Radiother Oncol; 2020 Apr; 145():229-237. PubMed ID: 32065903
[TBL] [Abstract][Full Text] [Related]
19. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4.
Miller RC; Schwartz DJ; Sloan JA; Griffin PC; Deming RL; Anders JC; Stoffel TJ; Haselow RE; Schaefer PL; Bearden JD; Atherton PJ; Loprinzi CL; Martenson JA
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1460-6. PubMed ID: 20800381
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer : Indication and technical considerations.
Hehr T; Baumann R; Budach W; Duma MN; Dunst J; Feyer P; Fietkau R; Haase W; Harms W; Krug D; Piroth MD; Sedlmayer F; Souchon R; Wenz F; Sauer R;
Strahlenther Onkol; 2019 Nov; 195(11):949-963. PubMed ID: 31451835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
